GlassScriptPhysician profile
Justin L Welch
NPI 1881798064
$9,728.29
in general payments reported to CMS, 2019-2025
35 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,100 · 2020: $679 · 2021: $1,176 · 2022: $1,588 · 2023: $2,069 · 2024: $1,879 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,008.28 |
| Education | $176.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,462.80 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $1,757.81 | 2020-2025 | |
| Janssen Biotech, INC. | $1,090.94 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,007.16 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $488.51 | 2019-2025 | Blu-U |
| E.R. Squibb & Sons, L.L.C. | $457.62 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $272.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $245.28 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $240.50 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $234.79 | 2019-2025 | Bimzelx |
| Amgen INC. | $210.10 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $186.39 | 2019-2024 | |
| Celgene Corporation | $114.12 | 2019 | |
| Galderma Laboratories, L.P. | $100.43 | 2021-2025 | Nemluvio |
| Aclaris Therapeutics, INC. | $95.59 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $94.70 | 2021-2022 | |
| Almirall LLC | $80.45 | 2021-2022 | |
| Merz North America, INC. | $79.06 | 2019-2023 | Xeomin |
| Fresenius Kabi USA, LLC | $68.61 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.37 | 2023 | Spevigo |
| Dusa Pharmaceuticals, INC. | $59.02 | 2019 | |
| Biofrontera INC. | $51.86 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ethicon US, LLC | $43.17 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $35.95 | 2019-2024 | Valchlor |
| Genentech USA, INC. | $28.79 | 2020-2021 | |
| Epi Health, LLC | $27.95 | 2021 | |
| Kerecis Limited | $23.07 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Organogenesis INC. | $18.28 | 2021 | |
| Organon LLC | $14.70 | 2024 | |
| Kyowa Kirin, INC. | $14.62 | 2022 | |
| Dermavant Sciences, INC. | $13.99 | 2024 | Vtama |
| Ani Pharmaceuticals, INC. | $13.97 | 2025 | Purified Cortrophin Gel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.43 | 2019 | |
| Merck Sharp & Dohme LLC | $11.22 | 2019 | |
| Prugen, INC. Pharmaceuticals | $10.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.